Carbon Nanotubes Conjugated to Tumor Lysate Protein Enhance the Efficacy of an Antitumor Immunotherapy

Meng, Jie; Duan, Jiaqi; Hua, Ke; Li, Li; Wang, Chen; Xie, Sishen; Chen, Shuchang; Gu, Ning; Xu, Haiyan; Yang, Xiao

doi:10.1002/smll.200701059

Cited by 121 publications

(75 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MWNTs have been conjugated to tumour lysate protein as an antigen. This specifically increased the antitumor immune response [48]. Glioma is a brain tumor that is able to evade the host immune system, resulting in lack of benefit from conventional chemotherapy.…”

Section: Cnts As Carriers Of Immunoactive Compounds Proteinsmentioning

confidence: 99%

Carbon Nanotubes in Cancer Therapy and Drug Delivery

Elhissi

Ahmed

Dhanak

et al. 2012

Emerging Nanotechnologies in Dentistry

View full text Add to dashboard Cite

Carbon nanotubes (CNTs) have been introduced recently as a novel carrier system for both small and large therapeutic molecules. CNTs can be functionalized (i.e., surface engineered) with certain functional groups in order to manipulate their physical or biological properties. In addition to the ability of CNTs to act as carriers for a wide range of therapeutic molecules, their large surface area and possibility to manipulate their surfaces and physical dimensions have been exploited for use in the photothermal destruction of cancer cells. This paper paper will discuss the therapeutic applications of CNTs with a major focus on their applications for the treatment of cancer.

show abstract

Section: Cnts As Carriers Of Immunoactive Compounds Proteinsmentioning

confidence: 99%

Carbon Nanotubes in Cancer Therapy and Drug Delivery

Elhissi

Ahmed

Dhanak

et al. 2012

Emerging Nanotechnologies in Dentistry

View full text Add to dashboard Cite

show abstract

“…Meng et al 118 conjugated MWCNTs to tumor lysate protein to enhance the efficacy of immunotherapy employing a tumor cell vaccine. In an H22 liver cancer-bearing mouse model, the efficacy of tumor curing and the cellular antitumor immune reaction in the tumor lysate protein-conjugated CNTs were markedly improved.…”

mentioning

confidence: 99%

Carbon nanotubes as cancer therapeutic carriers and mediators

Son¹,

Hong²,

Lee³

2016

IJN

206

105

View full text Add to dashboard Cite

Carbon nanotubes (CNTs) have received increasing attention in biomedical fields because of their unique structures and properties, including high aspect ratios, large surface areas, rich surface chemical functionalities, and size stability on the nanoscale. Particularly, they are attractive as carriers and mediators for cancer therapy. Through appropriate functionalization, CNTs have been used as nanocarriers for anticancer drugs including doxorubicin, camptothecin, carboplatin, cisplatin, paclitaxel, Pt(II), and Pt(IV), and genes including plasmid DNA, small-interfering RNA, oligonucleotides, and RNA/DNA aptamers. CNTs can also deliver proteins and immunotherapy components. Using combinations of light energy, they have also been applied as mediators for photothermal therapy and photodynamic therapy to directly destroy cancer cells without severely damaging normal tissue. If limitations such as a long-term cytotoxicity in the body, lack of size uniformity during the synthetic process, loading deviations for drug–CNT complexes, and release controllability at the target point are overcome, CNTs will become one of the strongest tools that are available for various other biomedical fields as well as for cancer therapy.

show abstract

“…Their results showed that this derivative, together with ovalbumin and an adjuvant, elicited high virus-neutralizing antibody responses in comparison with the non-conjugated peptide. Since this work, the advantages of immunization with proteins and 95 peptides using CNTs have occasionally been confirmed, [55][56][57][58] but, to the best of our knowledge, no evidence of an enhancement in the immune response and antibody production against small molecules using CNTs as vehicles has been reported. The production of antibodies displaying highaffinity and specificity to haptens is an important biotechnological research field because tailor-made binders can be used to develop immunoassays and biosensors for targets such as medicinal drugs, 100 pesticides, drugs of abuse, environmental contaminants, food additives, hormones, toxins, etc.…”

Section: Introductionmentioning

confidence: 95%

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Parra

Abad‐Somovilla

Mercader

et al. 2013

Journal of Controlled Release

View full text Add to dashboard Cite

Carbon nanotubes (CNTs) are nanomaterials with interesting emerging applications. Their 25 properties makes CNTs excellent candidates for use as new nanovehicles in drug delivery, immunization and diagnostics. In the current study, we assessed the immune-response-amplifying properties of CNTs to haptens by using azoxystrobin, the first developed strobilurin fungicide, as a model analyte. An azoxystrobin derivative bearing a carboxylated spacer arm (hapten AZc6) was covalently coupled to bovine serum albumin (BSA), and the resulting BSA-AZc6 conjugate was 30 covalently linked to four functionalized CNTs of different shapes and sizes, varying in diameter and length. These four types of CNT-based constructs were obtained using efficient, fast, and easy functionalization procedures based on microwave-assisted chemistry. New Zealand rabbits and BALB/c mice were immunized with BSA-AZc6 alone and with the four CNT-BSA-AZc6 constructs, both with and without Freund's adjuvant. The IgG-type antibody responses were assessed 35 in terms of the titer and affinity, paying special attention to the relationship between the immune response and the size and shape of the employed CNTs. Immunization with CNT-BSA-AZc6 resulted in enhanced titers and excellent affinities for azoxystrobin. More important, remarkable IgG responses were obtained even in the absence of an adjuvant, thus proving the self-adjuvanting capability of CNTs. Immunogens were able to produce strong anti-azoxystrobin immune responses 40 in rabbits even when administered at a BSA-AZc6 conjugate dose as low as 0.05 g. The short and thick CNT-BSA-AZc6 construct produced the best antibody response under all tested conditions.

show abstract

Carbon Nanotubes Conjugated to Tumor Lysate Protein Enhance the Efficacy of an Antitumor Immunotherapy

Cited by 121 publications

References 48 publications

Carbon Nanotubes in Cancer Therapy and Drug Delivery

Carbon Nanotubes in Cancer Therapy and Drug Delivery

Carbon nanotubes as cancer therapeutic carriers and mediators

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Contact Info

Product

Resources

About